Worth reading
66In focus
Scored from 4 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
339
¥ million (year-on-year increase in standalone sales)Wording
Avoiding a definitive answer
How definitive the wording is.Contents of this document
Earnings presentationInterim period of the fiscal year ending March 20275 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥491 million
Operating profit¥-331 million
Ordinary income¥-294 million
Net income¥-295 million
Results for the three months of the current quarter
Medical Product Promotion (July–September 2026)
Net Sales
¥51 million
Operating profit
¥-33 million
Ordinary income
¥-33 million
Net income
¥-33 million
Full-year earnings forecast
Net Sales
1,400～1,800
Operating profit
0～45
Ordinary income
40～85
Net income for the current fiscal year
40～85
What the company explained in this material
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
Milestone revenue from existing contracts, new license agreements and other sources. The timing of new contract execution and revenue recognition may vary. メディプロデュース is expected to generate sales of ¥300 million and zero profit over the 9-month period from July to March.New initiatives
- メディプロデュース became a consolidated subsidiary (effective 1 July 2026; acquisition price: ¥150 million)
- Financing capacity of up to approximately ¥2 billion through the 8th to 10th stock acquisition rights
- Achievement of LPO in TLM-001 Phase 2a and consideration of the development policy for the next stage
- Continuation of TLM-003 Phase 2 in Japan and overseas
- Preparation for additional clinical trials of TLG-001 in China
- Prototype development and evaluation through joint research between ReLight Tech and Tohoku University
Financial targets
Equity ratio: 42.5% (actual as of the end of September 2026)Market Size / Share
Global Myopia Population2050: approximately 4.76 billion people, 49.8% of the world's population
Japan Dry Eye Patient PopulationApproximately 22 million people
Global Dry Eye Patient PopulationApproximately 500 million to 3.4 billion people
Number of employees
Number of Employees22 (as of 31 March 2026, standalone)
Research personnel49 (including contracted researchers, as of April 2026)
| Item | Details |
|---|---|
| Document type | Earnings presentation |
| Fiscal Period Covered | Interim period of the fiscal year ending March 2027 |
| Net Sales | ¥491 million |
| Operating profit | ¥-331 million |
| Ordinary income | ¥-294 million |
| Net income | ¥-295 million |
| Results for the three months of the current quarter | Medical Product Promotion (July–September 2026) Net Sales ¥51 million / Operating profit ¥-33 million / Ordinary income ¥-33 million / Net income ¥-33 million |
| Full-year earnings forecast | Net Sales 1,400～1,800 / Operating profit 0～45 / Ordinary income 40～85 / Net income for the current fiscal year 40～85 |
| Number of employees | Number of Employees 22 (as of 31 March 2026, standalone) / Research personnel 49 (including contracted researchers, as of April 2026) |
| Assumptions Underlying the Business Outlook | Milestone revenue from existing contracts, new license agreements and other sources. The timing of new contract execution and revenue recognition may vary. メディプロデュース is expected to generate sales of ¥300 million and zero profit over the 9-month period from July to March. |
| Financial targets | Equity ratio: 42.5% (actual as of the end of September 2026) |
| Market Size / Share | Global Myopia Population 2050: approximately 4.76 billion people, 49.8% of the world's population / Japan Dry Eye Patient Population Approximately 22 million people / Global Dry Eye Patient Population Approximately 500 million to 3.4 billion people |
| New initiatives | メディプロデュース became a consolidated subsidiary (effective 1 July 2026; acquisition price: ¥150 million), Financing capacity of up to approximately ¥2 billion through the 8th to 10th stock acquisition rights, Achievement of LPO in TLM-001 Phase 2a and consideration of the development policy for the next stage, Continuation of TLM-003 Phase 2 in Japan and overseas, Preparation for additional clinical trials of TLG-001 in China, Prototype development and evaluation through joint research between ReLight Tech and Tohoku University |
Items this document does not state (18)
Gross Profit MarginOperating profit marginSelling, general and administrative expensesProgress against full-year forecastSelf-assessment against the planSegment resultsBreakdown of Factors Affecting the ChangeKey KPIsUnit price and quantity metricsNumber of stores and locationsRisk amount incorporated into the outlookMedium-term management plan targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Standalone sales increased due to milestone revenue from existing contracts. In the second half, the company aims to generate revenue from milestone payments under existing contracts, new license agreements and other sources, while adding capabilities in conference management, medical marketing and healthcare product sales through the consolidation of メディプロデュース as a subsidiary.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.